Synthesis and biological evaluation of some heterocyclic compounds
Keywords:Pyrrole, pyrrolo[2,3-d]pyrimidine, anticancer, HepG2, MCF-7, VEGFR-2
Cancer is one of the most striking diseases that has a potential impact on human health with high mortality rate. During the last century many anticancer agents have emerged but unfortunately, these agents could not provide effective solutions for cancer treatment due to side effects and resistance. All over the world, asking for new anticancer agents is still a major goal for medicinal chemists. Pyrrole and pyrrolo[2,3-d]pyrimidine scaffolds are very interesting bioactive core exhibiting several biological activities as anticancer, anti-inflammatory, antimicrobial activities. Herein, we highlighted on the anticancer activity of the pyrrole and pyrrolo[2,3-d]pyrimidine derivatives which are reported to possess anticancer activity and many of them are in market or still in clinical trials. This work deals with design and synthesis of new pyrrole and pyrrolopyrimidine derivatives. The new compounds were screened for their cytotoxic activity against HepG2 and MCF7in vitro. The most active compounds were evaluated for their VEGFR-2 inhibition in vitro
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, Global cancer statistics, CA: A Cancer Journal for Clinicians, 61, 69-90, (2011).
Ghorab MM, Ceruso M, Alsaid MS, Nissan YM, Arafa RK, Supuran CT, Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling, European Journal of Medicinal Chemistry, 87, 186-196(2014).
Zwick E, Bange J, Ullrich A, Receptor tyrosine kinase signalling as a target for cancer intervention strategies, Endocrine-Related Cancer, 8 , 161-173(2001).
Dholakia SP, Patel MM, Patel JS, Role of pyrrolopyrimidine derivatives as anticancer agent: minireview, Indo American Journal of Pharmaceutical Research, 5 , 858-867(2015).
Mannhold R, Kubinyi H, Folkers G, Klebl B, MüllerG, Hamacher M, Protein Kinases as Drug Targets, John Wiley & Sons, pp. 115-144(2011).
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, De Primo SE, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, Journal of Clinical Oncology, 24,16-24(2006).
Van Oosterom AT, Judson I, Verweij J, Stroobants S, Di Paola ED, Dimitrijevic S, Martens M, Webb A, SciotR, Van Glabbeke M, Safety andefficacy of imatinib (STI571) in metastaticgastrointestinalstromaltumours: a phase I study, The Lancet, 358 , 1421-1423(2001).
Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas, Journal of Clinical Oncology, 23 , 5305-5313(2005).
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, Erlotinib in previously treated non–small-cell lung cancer, New England Journal of Medicine, 353 , 123-132(2005).
Ghorab MM, Ragab FA, Heiba HI, Youssef HA, El-Gazzar MG, Synthesis of novel pyrrole and pyrrolo [2,3-d] pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents, Bioorganic & Medicinal Chemistry Letters, 20 ,6316-6320(2010).
Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R, Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma, The Oncologist, 12 ,107-113(2007).
Holmes K, Roberts OL, Thomas AM, Cross MJ, Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition, Cellular Signalling, 19 ,2003-2012(2007).
Semenza GL, N. Engl. J. Med., 358, 2066–7 (2008).
El Ella DAA, Ghorab MM, Noaman E, Heiba HI, Khalil AI, Molecular modeling study and synthesis of novel pyrrolo [2,3-d] pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities, Bioorganic & Medicinal Chemistry, 16 ,2391-2402 (2008).
Ann Transl Med.Dec; 2(12): 123 (2014).
Simard JR, Rauh D, Screening for allosteric kinase inhibitors in high-throughput: A novel fluorescence approach for detecting DFG-out kinase inhibitors, Screening-Trends in Drug Discovery, 2-4(2009).
Sapra S, Sharma K, Bhalla Y, Dhar KL, Chalconoid derived heterocycles as potent bioactive molecules, Chemical Sciences Journal, 7:2, 1-8(2016).
Mohamed MS, Abd El-Hameed RH, Sayed AI, Synthesis strategies and biological value of pyrrole and pyrrolopyrimidine,Journal of Advanced Pharmacy Research, 1, 1-24(2017).
Birnbaum LS, Garfield P, Journal of American Chemical Society, 67, 1464 – 1466(1945) .
Mosmann T, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, Journal of Immunological Methods, 65, 55-63 (1983).
Biovendor research and diagnostic products, Human VEGF-R2/KDR ELISA Product Data Sheet
Kitchen DB, Decornez H, Furr JR, Bajorath J, Docking and scoring in virtual screening for drug discovery: methods and applications, Nature Reviews Drug Discovery, 3, 935-949(2004).
El Ella DAA, Ghorab MM, Noaman E, Heiba HI, Khalil AI, Molecular modeling study and synthesis of novel pyrrolo [2,3-d] pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities, Bioorganic & Medicinal Chemistry, 16 ,2391-2402(2008).
Ismail M, Ghorab MM, Noaman E, Ammar YA, Heiba HI, Sayed MY, Novel synthesis of pyrrolo [2,3-d] pyrimidines bearing sulfonamide moieties as potential antitumor and radioprotective agents, Arzneimittel-Forschung, 56 ,301-308(2005).
Ghorab MM, Alsaid MS, Nissan YM, Synthesis and molecular docking of some novel anticancer sulfonamides carrying a biologically active pyrrole and pyrrolopyrimidine moieties, ActaPoloniaePharmaceutica, 71 ,603(2014).
Hilmy KMH, Khalifa MM, Hawata MAA, Keshk RMA, El-Torgman AA, Synthesis of new pyrrolo [2,3-d] pyrimidine derivatives as antibacterial and antifungal agents, European Journal of Medicinal Chemistry, 45, 5243-5250(2010).
Mohamed M, El-Domany R, Abd El-Hameed R, Synthesis of certain pyrrole derivatives as antimicro-bial agents, ActaPharmaceutica, 59, 145-158(2009).
Ghorab MM, Ragab FA, Noaman E, Heiba HI, El-Hossary EM, Synthesis of some novel quinolines and pyrimido [4,5-b] quinolines bearing a sulfonamide moiety as potential anticancer and radioprotective agents, Arzneimittel-Forschung, 57, 795-803(2006).
Mohamed MS, Kamel R, Fatahala SS, New condensed pyrroles of potential biological interest: Syntheses and structure-activity relationship studies, European Journal of Medicinal Chemistry, 46, 3022-3029(2011).
Ghorab MM, Heiba HI, Khalil AI, Abou El Ella DA, Noaman E, Computer-based ligand design and synthesis of some new sulfonamides bearing pyrrole or pyrrolopyrimidine moieties having potential antitumor and radioprotective activities, Phosphorus, Sulfur, and Silicon and the Related Elements, 183 ,90-104(2007).
El-Shaaer HM, Abdel-Aziz SAG, Hanafy FI, Ali TES, El-Fauomy AZ, Synthesis, antifungal activity and semi-empirical AM1-MO calculations of some new 4-oxo-4H-chromene derivatives, European Journal of Chemistry, 2, 158-162(2011).
Hranjec M, StarčevićK, PavelićSK, Lučin P, PavelićK, Zamola GK, Synthesis, spectroscopic characterization and antiproliferative evaluation in vitro of novel Schiff bases related to benzimidazoles, European Journal of Medicinal Chemistry, 46, 2274-2279(2011).
Pandeya S, Sriram D, Nath G, De Clercq E, Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4′-chlorophenyl) thiazol-2-yl] thiosemicarbazide, European Journal of Pharmaceutical Sciences, 9, 25-31(1999).
Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH, Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D 3 receptor ligands, Bioorganic & Medicinal Chemistry, 13, 77-87(2005).
Youngs C, Epp A, Craig B, Sallans H, Preparation of long-chain fatty acid chlorides, Journal of the American Oil Chemists Society, 34, 107-108 (1957).
Mohamed M.S, Fathallah SS, Pyrroles and fused pyrroles: synthesis and therapeutic activities, Mini-Reviews in Organic Chemistry, 11, 477-507(2014).
Bennett SM, Nghe NB, Ogilvie KK, Synthesis and antiviral activity of some acyclic and C-acyclic pyrrolo [2,3-d] pyrimidine nucleoside analogs, Journal of Medicinal Chemistry, 33 ,2162-2173(1990).
Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer, International Journal of Oncology, 39 ,271-278(2011).
Hicklin DJ, Ellis LM, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, Journal of Clinical Oncology, 23, 1011-1027(2005).
How to Cite
Copyright (c) 2020 Menna-Allah Mohamed, Yassin Mohamed, Nahed M. Eid, Flora F. Barsoum
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.